Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
1. EGRIFTA WR™ is now available for reducing abdominal fat in HIV patients. 2. The FDA approved EGRIFTA WR™ earlier this year for HIV-related lipodystrophy. 3. The new formulation simplifies administration with weekly reconstitution. 4. Specialty pharmacies are beginning to fill prescriptions for EGRIFTA WR™. 5. EGRIFTA WR™ is patent protected until 2033.